IONS — Ionis Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $6.07bn
- $5.01bn
- $787.65m
- 66
- 11
- 70
- 47
C2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 287 | -480 | -28.6 | -270 | -366 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 212 | 232 | 155 | -29 | 123 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -169 | -73.6 | -114 | 7.57 | -77.3 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 346 | 35.9 | 30.8 | -274 | -308 |
Capital Expenditures | -30.9 | -35.1 | -12 | -15.7 | -23.8 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -10.4 | 310 | 207 | -247 | -190 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Cash from Investing Activities | -41.3 | 274 | 195 | -263 | -214 |
Financing Cash Flow Items | -138 | -558 | -169 | -11 | 508 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 100 | -597 | 246 | -55.3 | 644 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 404 | -286 | 472 | -593 | 123 |